Study guide
6.3 Intravesical Chemotherapy & BCG Immunotherapy
FEBU Part 1 Written European Board of Urology
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & Exam Strategy
1.1 FEBU Part 1 Examination Structure & Logistics 1.2 EAU Guidelines Framework & Standard Setting 1.3 Clinical Decision-Making & MCQ Strategy 1.4 Professionalism and Safe Practice
2 Chapter 2: Genitourinary Anatomy & Renal Physiology
2.1 Upper Tract Anatomy & Retroperitoneal Relationships 2.2 Lower Urinary Tract Anatomy & Neuroanatomy 2.3 Renal Physiology, Glomerular Filtration & Acid-Base Balance
3 Chapter 3: Urological Pharmacology & Diagnostic Imaging
3.1 Lower Urinary Tract Pharmacotherapy 3.2 Antimicrobial Stewardship & Perioperative Care 3.3 Diagnostic Modalities: Ultrasound, CT, mpMRI & Nuclear Medicine
4 Chapter 4: Prostate Cancer: Diagnosis & Risk Stratification
4.1 PSA Kinetics, Biomarkers & Risk Assessment 4.2 Multiparametric MRI (PI-RADS) & Biopsy Strategies 4.3 Histopathological Grading (ISUP Gleason) & Staging
5 Chapter 5: Prostate Cancer: Localized & Advanced Management
5.1 Active Surveillance & Watchful Waiting 5.2 Radical Prostatectomy & Radiation Therapy 5.3 Biochemical Recurrence & Salvage Therapies 5.4 Metastatic & Castration-Resistant Prostate Cancer (CRPC)
6 Chapter 6: Bladder Cancer: Non-Muscle Invasive (NMIBC)
6.1 TURBT Technique & Pathological Staging 6.2 EAU Risk Stratification for NMIBC 6.3 Intravesical Chemotherapy & BCG Immunotherapy
7 Chapter 7: Muscle-Invasive Bladder Cancer & Upper Tract Urothelial Carcinoma
7.1 Muscle-Invasive Bladder Cancer (MIBC) Staging & Neoadjuvant Therapy 7.2 Radical Cystectomy & Urinary Diversion 7.3 Upper Tract Urothelial Carcinoma (UTUC)
8 Chapter 8: Renal Cell Carcinoma & Adrenal Neoplasms
8.1 Histological Subtypes, Genetics & Staging of RCC 8.2 Localized RCC: Nephron-Sparing Surgery & Radical Nephrectomy 8.3 Metastatic RCC & Targeted / Immunotherapy Regimens 8.4 Adrenal Masses & Incidentalomas
9 Chapter 9: Testicular Germ Cell Tumours & Penile Cancer
9.1 Testicular Cancer Diagnosis, Staging & Tumour Markers 9.2 Management of Seminoma (Stage I to Metastatic) 9.3 Management of Non-Seminoma (Stage I to Metastatic) 9.4 Penile Cancer: Staging, Organ-Sparing & Lymphadenectomy
10 Chapter 10: Benign Prostatic Hyperplasia & Lower Urinary Tract Symptoms
10.1 BPH Pathophysiology, Natural History & Clinical Evaluation 10.2 Medical Management of Male LUTS / BPO 10.3 Interventional & Surgical Management of BPO
11 Chapter 11: Functional Urology, Incontinence & Neuro-Urology
11.1 Urinary Incontinence in Men and Women, Fistulae & Urethral Diverticula 11.2 Overactive Bladder, Bladder Pain Syndrome & Pelvic Organ Prolapse 11.3 Neurogenic Lower Urinary Tract Dysfunction (NLUTD) 11.4 Urodynamic Studies: Indications, Technique & Interpretation
12 Chapter 12: Urolithiasis: Evaluation & Medical Management
12.1 Stone Pathophysiology & Risk Factors 12.2 Metabolic Evaluation & Dietary/Medical Stone Prevention 12.3 Acute Ureteric Colic & Medical Expulsive Therapy
13 Chapter 13: Endourology & Interventional Stone Management
13.1 Shock Wave Lithotripsy (SWL) 13.2 Ureteroscopy (URS) & Retrograde Intrarenal Surgery (RIRS) 13.3 Percutaneous Nephrolithotomy (PCNL) & Endourological Safety
14 Chapter 14: Infections, Andrology & Male Infertility
14.1 Localised & Systemic UTIs, Pyelonephritis, Urosepsis & Specific Infections 14.2 Prostatitis, Epididymo-Orchitis & Fournier Gangrene 14.3 Male Infertility: Evaluation & Surgical Management 14.4 Erectile Dysfunction, Peyronie Disease, Priapism & Gender-Affirming Surgery
15 Chapter 15: Paediatric Urology, Trauma & Renal Transplantation
15.1 Cryptorchidism, Hypospadias & PUJO 15.2 Vesicoureteral Reflux, Posterior Urethral Valves & Nocturnal Enuresis 15.3 Genitourinary Trauma: Kidney, Bladder & Urethra 15.4 Renal Failure, Dialysis Indications & Renal Transplantation
6.3 Intravesical Chemotherapy & BCG Immunotherapy
Key Takeaways Explain This Topic AI
Offer eligible low-risk or selected recurrent papillary NMIBC patients a single immediate chemotherapy instillation within 24 hours, preferably in the first two hours. EAU cites five-year recurrence 59%→45%, a 14-percentage-point absolute reduction.
Withhold immediate intravesical chemotherapy for suspected/overt perforation or bleeding requiring bladder irrigation. Extensive deep resection raises concern for extravasation; assess safety before instillation.
BCG induction comprises six weekly instillations. Give maintenance for optimal efficacy: one year for intermediate risk when BCG is selected, and 1–3 years for high risk. Three years reduces high-risk recurrence versus one year; a progression or survival advantage was not shown.
Suspected systemic BCG infection requires urgent assessment and stopping BCG. BCG sepsis needs resuscitation, multidrug antimycobacterial treatment and early systemic corticosteroids. M. bovis is resistant to pyrazinamide; do not rely on it.
BCG-unresponsive disease includes refractory disease and early HG relapse after adequate BCG: Ta/T1 within 6 months or CIS within 12 months. Radical cystectomy is the preferred standard in fit patients; distinguish BCG-exposed disease and LG recurrence, which may allow other treatment.
Last updated: November 2026
6.3 Intravesical Chemotherapy & BCG Immunotherapy
Adjuvant intravesical therapy is essential to reduce the substantial risks of recurrence and progression following complete TURBT in non-muscle-invasive bladder cancer (NMIBC). Clinical strategies divide broadly into two categories: intravesical chemotherapy (a single immediate instillation for eligible papillary disease, or adjuvant courses mainly for intermediate risk) and intravesical Bacillus Calmette-Guérin (BCG) immunotherapy (standard bladder-preserving treatment for high risk and selected very high risk after discussion of cystectomy).
- 1. Immediate Single Post-Operative Instillation (SI) of Chemotherapy
- Biological Rationale and Clinical Evidence
TURBT inevitably dislodges viable neoplastic cells into the irrigating fluid. These circulating cells readily implant onto traumatized urothelial basement membrane and resection crater sites. Concurrently, microscopic residual tumor cells at the surgical margins may persist.
An immediate single instillation of cytotoxic chemotherapy destroys free-floating cells and ablates residual microscopic clonogenic foci.
Efficacy : EAU cites an individual-patient meta-analysis showing five-year recurrence 59%→45% , an absolute reduction of 14 percentage points . Benefit was seen in primary tumours and selected recurrent intermediate-risk tumours with low prior recurrence rate/low EORTC recurrence score; SI alone is insufficient for many higher-recurrence-risk patients.
Timing : Give SI within 24 hours , as soon as safely feasible and preferably in the first two hours . Early treatment targets implantation before cells become firmly attached/covered by extracellular matrix.
Chemotherapeutic Agents
Mitomycin C (MMC) : 40 mg dissolved in 20–40 mL of sterile water or normal saline, retained in the bladder for 1 to 2 hours.
Epirubicin : 50–80 mg in 50 mL sterile water.
Gemcitabine : 1,000–2,000 mg in 50–100 mL saline. An immediate gemcitabine instillation reduced recurrence versus saline with low toxicity in SWOG S0337. There is no randomized SI comparison establishing equivalence or universal superiority over MMC.
Absolute Contraindications to Immediate Instillation
Documented or Suspected Bladder Perforation : Extraperitoneal or intraperitoneal extravasation of cytotoxic chemotherapy causes severe perivesical fat necrosis, retroperitoneal phlegmon, intractable pelvic fibrosis, enterovesical or vesicocutaneous fistulae, and potentially fatal systemic myelosuppression.
Bleeding Requiring Bladder Irrigation : Omit SI; ongoing bleeding and extensive resection raise absorption/extravasation concerns and irrigation prevents effective drug retention.
Extensive Deep Resection : Extensive resection near the perivesical fat carries high risk of occult microperforation.
Caution
If there is any clinical or endoscopic suspicion of bladder perforation, or if bladder irrigation fluid fails to return with clear fluid and accurate volumes, the immediate post-operative chemotherapy instillation must be withheld.
2. Adjuvant Chemotherapy for Intermediate-Risk Disease & Optimization
For intermediate-risk NMIBC, induction intravesical chemotherapy, with or without maintenance for up to one year, reduces recurrence and usually causes fewer adverse effects than BCG:
Example Schedule : Six weekly induction instillations, with monthly maintenance if selected. The optimal schedule and maintenance benefit remain uncertain; EAU advises not exceeding one year.
Pharmacokinetic Optimization of Mitomycin C :
Urine Alkalinization : MMC is less stable in acidic urine. The Au 2001 optimized regimen used sodium bicarbonate 1.3 g the night before, morning of and 30 minutes before treatment; alkalinization helps preserve active drug, rather than guaranteeing one pH target in every patient.
Fluid Restriction : The optimized trial restricted drinking for eight hours before and during treatment to reduce urine production and dilution. Apply an appropriate local protocol.
Complete Bladder Emptying : Residual urine is completely drained via catheter before instilling the drug.
Bundled Optimization : Au 2001 compared 40 mg/20 mL plus alkalinization, low residual urine and fluid restriction with 20 mg/20 mL without these manipulations. Better recurrence control supports the bundle, not an isolated proof that 40 mg/20 mL is superior to 40 mg/40 mL.
Device-Assisted Chemotherapy :
Radiofrequency-Induced Chemohyperthermia (RF-CHT) and Hyperthermic Intravesical Chemotherapy (HIVEC) : Heating the bladder mucosa to 41–43°C increases urothelial permeability, inhibits DNA repair mechanisms, and enhances MMC cytotoxicity.
Electromotive Drug Administration (EMDA) : Uses an electrical current to enhance MMC transport across the urothelium.
3. Intravesical Bacillus Calmette-Guérin (BCG): Mechanism & Immunology
Bacillus Calmette-Guérin is a live, attenuated strain of Mycobacterium bovis . Maintenance BCG is more effective than chemotherapy for recurrence prevention. Evidence also supports reduced progression versus mixed control treatments, but a progression/survival advantage over MMC was not confirmed in the individual-patient meta-analysis; distinguish recurrence from progression endpoints. +-------------------------------------------------------------------------------+
- | BCG IMMUNOLOGICAL CASCADE IN THE BLADDER |
- +-------------------------------------------------------------------------------+
- | 1. Intraluminal Instillation of Live Attenuated Mycobacterium bovis |
- | v |
- | 2. Urothelial Attachment via Fibronectin Attachment Protein (FAP) |
- | - Binds exposed basement membrane fibronectin in resection bed |
- | v |
- | 3. Internalization into Urothelial & Carcinoma Cells via Macropinocytosis |
- | v |
- | 4. Massive Cytokine & Chemokine Release: |
- | - IL-1, IL-2, IL-6, IL-8, IL-12, IFN-gamma, TNF-alpha, GM-CSF |
- | v |
- | 5. Recruitment of Effector Immune Infiltrate: |
- | - CD4+ Helper T cells (Th1 polarization) & CD8+ Cytotoxic T Lymphocytes |
- | - Natural Killer (NK) cells, Macrophages, Granulocytes |
- | v |
- | 6. Target Cell Lysis: MHC Class I/II presentation, Perforin/Granzyme-mediated|
- | destruction of neoplastic urothelium & granuloma formation |
- +-------------------------------------------------------------------------------+
- Key Phases of the Immune Cascade
Fibronectin Binding : BCG express fibronectin attachment protein (FAP), which binds avidly to fibronectin deposited on traumatized urothelial basement membranes.
Cellular Internalization : BCG is internalized by normal and malignant urothelial cells via macropinocytosis.
Th1-Polarized Cytokine Response : Ingestion stimulates the release of pro-inflammatory cytokines: Interleukin-2 (IL-2), Interleukin-12 (IL-12), Interferon-gamma (IFN-γ), and Tumor Necrosis Factor-alpha (TNF-α). A robust Th1 cytokine profile correlates with successful clinical response.
Cytotoxic Effector Lysis : Activated CD8+ cytotoxic T lymphocytes and NK cells recognize tumor antigens and eliminate residual microscopic cancer cells, accompanied by suburothelial non-caseating granuloma formation.
4. BCG Treatment Schedules: Induction & Maintenance
Do not give BCG during the first two weeks after TURBT ; defer further if mucosal injury, visible haematuria or symptomatic infection persists. Healing limits systemic absorption of live mycobacteria.
Induction Course (Morales Regimen)
Consists of 6 consecutive weekly intravesical instillations .
Maintenance is required for optimal efficacy; induction alone has less reliable recurrence control.
Maintenance Protocols: The SWOG Regimen
The Southwest Oncology Group (SWOG 8507 / Lamm protocol) established the therapeutic standard:
3 weekly instillations administered at months 3, 6, 12, 18, 24, 30, and 36 (total of 27 instillations over 3 years).
Duration by Risk Group :
High-Risk NMIBC : Full-dose BCG for one to three years . Three years improves recurrence control versus one year, without demonstrated progression or overall-survival improvement; balance added treatment against toxicity and access.
Intermediate-Risk NMIBC : If BCG is chosen, one year (induction plus three-week boosters at 3, 6 and 12 months); longer maintenance has not shown additional benefit in this group.
Dose Reduction for Toxicity : Reduced-dose BCG may lessen adverse effects, but can increase recurrence and does not consistently reduce toxicity. Do not promise preserved efficacy; consider symptom severity, risk, postponement and available treatment with the patient.
5. Adverse Effects & Management of BCG Toxicity
Up to 70–80% of patients experience some degree of adverse reaction during BCG therapy. Distinguishing expected local immune inflammation from life-threatening systemic mycobacterial dissemination is critical.
Local Toxicities
Chemical / Immune Cystitis : Dysuria, urinary frequency, urgency, and low-grade pyuria occurring within 24–48 hours of instillation.
Management : Symptom-directed treatment such as mirabegron, phenazopyridine or NSAIDs. If symptoms persist or worsen, postpone BCG, obtain urine culture and evaluate/treat infection; do not substitute automatic dose reduction for assessment.
Haematuria : Often transient, but visible blood requires postponing BCG. Investigate persistent bleeding, including cystoscopy to exclude tumour; microscopic haematuria alone is not a contraindication.
Severe Local and Systemic Complications (BCGitis)
Presentation Assessment Immediate Management Antimicrobial Treatment
Fever >38.5°C for >48 hours Infection or significant systemic reaction; investigate promptly Stop BCG permanently; cultures, blood tests, chest imaging and infectious-disease consultation Prompt multidrug antimicrobial treatment while evaluating; tailor the regimen and duration to the diagnosis
BCG Sepsis / Septic Shock Suspected disseminated infection; also cover conventional bacterial sepsis ICU resuscitation, fluids/vasopressors as needed, permanent cessation of BCG and early systemic corticosteroids Isoniazid 300 mg/day, rifampicin 600 mg/day and ethambutol (EAU adult example 1.2 g/day), usually six months for severe infection under specialist care; empirical bacterial coverage as indicated
Symptomatic Granulomatous Prostatitis Urine culture and specialist assessment Stop intravesical therapy; assess for abscess Quinolone initially; if ineffective, EAU lists isoniazid 300 mg/day plus rifampicin 600 mg/day for three months
Epididymo-orchitis Culture and assess for abscess or other infection Stop BCG; urology/infectious-disease review Appropriate antimicrobial treatment; orchidectomy may be needed for abscess or failure to respond
Mycobacterial Pneumonitis / Hepatitis Dissemination with possible hypersensitivity component Stop BCG and obtain urgent specialist evaluation Multidrug anti-TB treatment directed by disease and organ function; systemic corticosteroids for severe systemic reaction
Warning
Mycobacterium bovis is intrinsically resistant to pyrazinamide . Do not rely on pyrazinamide. Isoniazid, rifampicin and ethambutol are the usual drugs for serious systemic BCG infection; regimen and duration depend on the clinical manifestation, with corticosteroids used for severe systemic reactions.
Absolute Contraindications to BCG Instillation
Prior systemic BCG sepsis or severe hypersensitivity reaction.
Active, gross hematuria (indicates disrupted vascular barrier).
Traumatic or difficult catheterization (catheter-induced mucosal tear).
During the first two weeks after TURBT, or while traumatic mucosal injury remains unhealed.
Symptomatic UTI . Asymptomatic bacteriuria, leukocyturia and microscopic haematuria alone do not preclude BCG.
Immunosuppression: EAU treats it as a relative contraindication requiring specialist assessment; severe immunodeficiency may preclude a live BCG product under its prescribing information. Transplant status or HIV infection alone should not be equated to a universal absolute prohibition.
6. Definitions of BCG Failure: EAU Consensus
Recognizing BCG failure is crucial because continuing ineffective intravesical therapy in high-grade disease delays life-saving radical cystectomy. The EAU categorizes BCG failure into distinct clinical entities:
BCG-Refractory :
T1 HG/G3 at the three-month assessment.
Persistent Ta HG/G3 after further BCG (re-induction or first maintenance), assessed at three/six months.
CIS at three months persisting at six months after re-induction or first maintenance; CIS at three months after induction alone can still respond to another course.
HG tumour appearing during maintenance.
BCG-Relapsing : HG recurrence after an initial response and completion of maintenance. The clinically important early-relapse windows differ by disease type: six months for Ta/T1 HG, twelve months for CIS .
BCG-Unresponsive : All refractory tumours, plus Ta/T1 HG recurrence within six months or CIS within twelve months of completing adequate BCG.
Adequate BCG : At least 5/6 induction doses , plus 2/6 doses of a second induction or 2/3 maintenance doses .
BCG-Exposed : HG disease after BCG that does not meet unresponsive criteria, including Ta HG/CIS at three months after induction alone or selected delayed relapses. Additional BCG may benefit selected patients.
BCG-Intolerant : Severe adverse effects prevent completion of treatment.
LG recurrence is not BCG failure. Any progression to muscle-invasive disease requires management on the invasive-cancer pathway rather than another NMIBC instillation algorithm.
7. Management of BCG-Unresponsive Disease
BCG-unresponsive tumours are unlikely to benefit from further BCG. Assess restaging and timely definitive treatment rather than assigning one progression percentage to heterogeneous patients or persisting with ineffective instillations.
Standard of Care: Immediate Radical Cystectomy (RC) :
Radical cystectomy with bilateral pelvic lymphadenectomy is the primary therapeutic benchmark endorsed by EAU and international consensus guidelines.
Arrange cystectomy promptly when selected; progression before definitive surgery can worsen prognosis.
Bladder-Sparing Salvage Strategies (Strictly for patients unfit for or adamantly refusing RC) :
Pembrolizumab : Intravenous anti-PD-1 immune checkpoint inhibitor; FDA-approved , without a current EMA NMIBC indication, for BCG-unresponsive high-risk CIS with/without papillary tumours when cystectomy is declined or unsuitable. KEYNOTE-057 showed 41% complete response at three months; 46% of responders maintained response for at least 12 months, approximately 19% of the full efficacy cohort.
Nadofaragene Firadenovec : Non-replicating adenoviral vector delivering human interferon-alpha-2b cDNA directly into urothelial cells. The phase III single-arm trial found 53.4% CIS complete response within three months; 45.5% of those responders remained free of HG recurrence at twelve months. FDA-approved; conditional EU authorisation was granted on 28 May 2026 for BCG-unresponsive CIS with/without papillary tumours.
Sequential Intravesical Chemotherapy : Dual intravesical gemcitabine and docetaxel administered sequentially has predominantly retrospective evidence; one BCG-unresponsive cohort reported 65% and 49% HG recurrence-free survival at twelve and 24 months. It is an option when cystectomy is declined or unsuitable, not proof of equivalent long-term cancer control to surgery.
Device-Assisted Chemotherapy : Radiofrequency-induced chemohyperthermia (RF-CHT) with MMC.
8. Intravesical Instillation Protocols & BCG Toxicity Management Comparison Table
Parameter Immediate Single Instillation (SI) Chemotherapy Adjuvant Maintenance Chemotherapy Adjuvant BCG Immunotherapy
Primary Indication Low risk and selected recurrent papillary disease Intermediate-risk NMIBC High risk, selected intermediate/VHR bladder preservation after risk discussion
Typical Drugs & Doses Mitomycin C (40 mg), Epirubicin (50–80 mg), Gemcitabine (1–2 g) Mitomycin C (40 mg optimized with oral bicarbonate) Live attenuated M. bovis (Tice, Connaught, RIVM strains; 1 vial)
Timing of First Instillation Within 24 hours, preferably first two hours 2 to 4 weeks post-TURBT after urothelial healing At least two weeks after TURBT, with healing; defer for visible haematuria
Treatment Schedule Single dose Example: six weekly induction ± maintenance, total ≤one year; optimal schedule uncertain Six-week induction; three-week maintenance cycles at 3, 6, 12 months, extending to 18, 24, 30, 36 months when selected for high risk
Primary Mechanism Cytotoxic ablation of circulating cells and margin micro-foci Intermittent inhibition of DNA replication and cell division Robust Th1 cell-mediated immune activation and cytokine cytotoxic lysis
Common Toxicities Chemical cystitis, palmar/perineal contact dermatitis (rash) Irritative voiding symptoms, bladder wall calcification/fibrosis Irritative cystitis (75%), low-grade pyrexia, transient flu-like symptoms
Severe Complications Perivesical extravasation causing pelvic necrosis; severe myelosuppression Chemical contraction of bladder capacity Systemic BCGitis, mycobacterial sepsis, granulomatous prostatitis, hepatitis
Key Contraindications Suspected/overt perforation, bleeding requiring irrigation, extensive/deep resection with extravasation concern Active perforation, gross hematuria, severe drug allergy Visible haematuria, traumatic catheterisation, symptomatic UTI, first two post-TURBT weeks, previous BCG sepsis; assess immunosuppression individually